AVAX Technologies Announces Expansion of Clinical Study with Autologous Ovarian Cancer Vaccine (OVax®)
12 2월 2014 - 12:17AM
Business Wire
~ Clinical data from the study to be
presented at the Society of Gynecologic Oncology 19th
Annual Winter Meeting February 20 – 22nd,
2014
AVAX Technologies, Inc. (other OTC: “AVXT”) today announces it
has expanded its ongoing Phase 1/2 study (“Trial of Autologous,
Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III
or IV Ovarian Cancer”) to include all five Cancer Treatment Centers
of America® (CTCA) regional hospitals. In addition, clinical data
from the study was selected to be presented at the Society of
Gynecologic Oncology (“SGO”) 19th Annual Winter Meeting February 20
– 22, 2014 at Breckenridge, Colorado. The SGO is the premier
medical specialty society for health care professionals trained in
the comprehensive management of gynecologic cancers.
“We are enthusiastic about continuing and expanding the clinical
study with Cancer Treatment Centers of America,” stated Richard
Rainey, Chief Executive Officer of AVAX. “We were honored to have
our abstract selected for presentation at the SGO winter meeting
and look forward to further communicating the interim trial results
on the date of the presentation.”
Dr. David Berd, Chief Medical Officer of AVAX noted, “We are
collaborating with CTCA to explore additional studies and protocols
to offer additional treatment alternatives to their patients.”
“We are very excited to be part of a new chapter in the fight
against ovarian cancer,” said Dr. Giuseppe Del Priore, National
Director of Gynecologic Oncology at Cancer Treatment Centers of
America. “Ovarian cancer is a very complex cancer that is often
resistant to chemotherapy, radiation and surgery. At Cancer
Treatment Centers of America, our commitment to cancer patients is
to help fight their cancer with advanced medical technologies. This
study works well with our unique care model, which combines
rigorous, evidenced based state-of-the-art medicine with
scientifically-based integrative therapies such as aggressive
nutritional management, naturopathic medicine, physical therapy,
and spiritual support, going beyond treating just the tumor to
supporting the needs of the whole person.”
About the AC Vaccine Therapeutic
The AC Vaccine is an immunotherapy prepared by attaching a small
chemical to the patient’s tumor cells in a process known as
haptenization. This hapten modification allows the tumor cells to
stimulate a T cell-based immune response to a patients own tumor
cells. An early indicator of T cell immune activity is Delayed Type
Hypersensitivity (DTH).
An understanding of what AVAX calls the immunopharmacology of
the AC Vaccines is critical to their effective use. AVAX believes
that the optimal dose, schedule of administration, and route of
administration of human cancer vaccines must be established before
they enter advanced phase studies, and that some competing vaccine
technologies have failed because their developers ignored one or
more of these parameters in early phase development.
About Ovarian Cancer
The American Cancer Society reports that ovarian cancer is the
eighth most common cancer among women and is the fifth leading
cause of cancer related deaths in women. It is estimated that there
will be 22,240 new cases of ovarian caner in the U.S. in 2013 and
14,000 cancer related deaths.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national
network of hospitals focusing on complex and advanced stage cancer.
CTCA offers a comprehensive, fully integrated approach to cancer
treatment and serves patients from all 50 states at facilities
located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known
for delivering the Mother Standard® of care and Patient Empowerment
Medicine®, CTCA provides patients with information about cancer and
their treatment options so they can control their treatment
decisions. For more information about CTCA, go to
www.cancercenter.com.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company with
operations in the United States and Europe. The Company is engaged
in the research, clinical and commercial development of biological
products and cancer therapeutics. AVAX’s AC Vaccine platform is a
therapeutic cancer vaccine. In addition, the Company performs
contract-manufacturing services for biological products for other
pharmaceutical and biotechnology companies.
Except for statements that are historical, the statements in
this release are "forward-looking" statements that are made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Forward-looking statements involve significant risks
and uncertainties, and in light of the significant uncertainties
inherent in such statements, the inclusion of such information
should not be regarded as a representation by AVAX that the
objectives and plans of the Company will be achieved. In fact,
actual results could differ materially from those contemplated by
such forward-looking statements. Many important factors affect the
Company's prospects, including (1) risk associated with a change in
executive management of the Company, (2) the immediate need to
obtain additional funding to continue to finance the Company’s
development plans, including the Phase I-II clinical trial for OVax
described in this press release, (3) the results of clinical and
laboratory testing of its vaccine technologies, (4) the Company's
ability to maintain its rights under license agreements and to meet
funding requirements under its license agreements, (5) the
Company's ability to demonstrate the safety and efficacy of product
candidates at each stage of development and to meet applicable
regulatory standards and receive required regulatory approvals, as
well as other risks detailed from time to time in AVAX's previous
public disclosure filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-KSB. AVAX does
not undertake any obligation to release publicly any revisions to
these forward-looking statements or to reflect the occurrence of
unanticipated events.
AVAX Technologies, Inc.David Berd, MD,
847-342-6856www.avax-tech.comorCTCASusan Morris,
215-241-9760www.cancercenter.com
AVAX Technologies (CE) (USOTC:AVXT)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
AVAX Technologies (CE) (USOTC:AVXT)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
